Search Within

Matthew J Matasar

  1. "Carol Portlock"
  2. "Lymphoma"
  3. "Population Sciences Research Program"
  4. "John Gerecitano"
  5. "Executive Committee, Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (7)
Groups
  1. Center for Hematologic Malignancies (23)
  2. Department of Medicine (23)
  3. Executive Committee, Center for Hematologic Malignancies (23)
  4. Hematologic Malignancies, Division of (23)
  5. Lymphoma (23)
  6. Population Sciences Research Program (23)

More Groups

People
  1. Alison Moskowitz (23)
  2. Anas Younes (23)
  3. Andrew Zelenetz (23)
  4. Ariela Noy (23)
  5. Carol Portlock (23)
  6. Craig Moskowitz (23)

More People

Years
  1. 2021 (1)
  2. 2019 (1)
  3. 2018 (1)
  4. 2017 (10)
  5. 2016 (4)
  6. 2015 (3)

More Years

Publications
  1. Blood (14)
  2. Hematological Oncology (3)
  3. Blood Advances (1)
  4. Blood Cancer Journal (1)
  5. Clinical Cancer Research (1)
  6. Clinical Lymphoma, Myeloma and Leukemia (1)

More Publications

Publishers
  1. American Society of Hematology (15)
  2. Wiley Blackwell (3)
  3. American Association for Cancer Research (1)
  4. Elsevier Inc. (1)
  5. Elsevier Science, Inc. (1)
  6. Ferrata Storti Foundation (1)

More Publishers

Results (23)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
    Journal Article

    Joffe, E.; Leyfman, Y.; Drill, E.; Rajeeve, S.; Zelenetz, A. D.; Lia Palomba, M.; Moskowitz, C. H.; Portlock, C.; Noy, A.; Horwitz, S. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
    Journal Article

    Borchmann, S.; Joffe, E.; Moskowitz, C. H.; Zelenetz, A. D.; Noy, A.; Portlock, C. S.; Gerecitano, J. F.; Batlevi, C. L.; Caron, P. C.; Drullinsky, P.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay
    Journal Article

    Intlekofer, A. M.; Joffe, E.; Batlevi, C. L.; Hilden, P.; He, J.; Seshan, V. E.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, C. H.; Portlock, C.; more...
    Blood Cancer Journal (2018)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Genomic characteristics clinical phenotype and disease course of TP53 mutated diffuse large B cell lymphoma at diagnosis and relapse
    Meeting Abstract

    Joffe, E.; Batlevi, C. L.; Intlekofer, A. M.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Noy, A.; Straus, D. J.; Portlock, C. S.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Active surveillance for newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma
    Meeting Abstract

    Borchmann, S.; Joffe, E.; Moskowitz, C. H.; Zelenetz, A. D.; Noy, A.; Portlock, C. S.; Gerecitano, J. F.; Batlevi, C.; Caron, P.; Drullinsky, P.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era treated at Memorial Sloan Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P.; Horwitz, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2017)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save